1103738-19-7

Basic information

• Product Name: D-xylo-Pentodialdo-5,2-furanose, 4,5-O-(1-Methylethylidene)-1-C-4-Morpholinyl-,(5S)-
• Synonyms: D-xylo-Pentodialdo-5,2-furanose, 4,5-O-(1-Methylethylidene)-1-C-4-Morpholinyl-,(5S)-;((3aS,5R,6S,6aS)-6-hydroxy-2,2-diMethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)(Morpholino)Methanone;(3aS,5R,6S,6aS)-[6-hydroxy-2,2-dimethyltetrahydrofuro[3,2-d][1,3]dioxol-5-yl]-(morpholino)methanone;EOS-61383;LX-4211 int;(5S)-4,5-O-(1-Methylethylidene)-1-C-4-morpholinyl-D-xylo-pentodialdo-5,2-furanose;LX-4211 inermediate;(5S)-4,5-O-(1-Methylethylidene)-1-C-4-morpholinyl-D-xylo-pentodialdo-5,2-furanose
• CAS NO: 1103738-19-7
• Molecular Formula: C₁₂H₁₉NO₆
• Molecular Weight: 273.28236
• Mol File: 1103738-19-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 479.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.318±0.06 g/cm3(Predicted)
• PKA: 12.78±0.60(Predicted)
• CAS DataBase Reference: D-xylo-Pentodialdo-5,2-furanose, 4,5-O-(1-Methylethylidene)-1-C-4-Morpholinyl-,(5S)-(CAS DataBase Reference)
• NIST Chemistry Reference: D-xylo-Pentodialdo-5,2-furanose, 4,5-O-(1-Methylethylidene)-1-C-4-Morpholinyl-,(5S)-(1103738-19-7)
• EPA Substance Registry System: D-xylo-Pentodialdo-5,2-furanose, 4,5-O-(1-Methylethylidene)-1-C-4-Morpholinyl-,(5S)-(1103738-19-7)

Safety Data

• Hazardous Substances Data: 1103738-19-7(Hazardous Substances Data)

Usage

General Description

"D-xylo-Pentodialdo-5,2-furanose, 4,5-O-(1-Methylethylidene)-1-C-4-Morpholinyl-,(5S)-" is a chemical compound with a complex structure. The exact physical and chemical properties of this compound are not readily available to the public domain, suggesting that it may not be widely used or researched. Based on its nomenclature, it appears to include a sugar component (D-xylo-Pentodialdo-5,2-furanose) which has been modified with addition of a morpholine group (a common component in many pharmaceuticals) and a methylethylidene group. The "(5S)-" at the end of the name indicates it has a specific orientation in space (chirality), often an important feature in bioactive molecules. Due to its complex structure, this compound likely requires specialized techniques for its synthesis.

Upstream product

• 87-72-9 L-xylopyranose 
• 41546-31-0 L-xylose 
• 110-91-8 morpholine 
• 108-21-4 Isopropyl acetate 
• 1352955-16-8 (3aS,5R,6S,6aS)-5-hydroxymethyl-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxolane-6-ol 
• 109-02-4 4-methyl-morpholine 
• 1103738-17-5 (3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxolane-5-carboxylic acid 
• 87-72-9 D-Xylose 
• 131156-47-3 (3aS,3bR,7aS,8aS)-2,2,5,5-tetramethyltetrahydro-3aH-[1,3]dioxolo[4',5':4,5]furo[3,2-d][1,3]dioxane 
• 114861-22-2 1,2-O-isopropylidene-α-L-xylofuranose 
• 609-06-3 L-xylose 
• 1103738-20-0 morpholine (3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carboxylic acid 

Downstream Products

• 1103738-30-2 (4-chloro-3-(4-ethoxybenzyl)phenyl)((3aS,5R,6S,6aS)-6-hydroxy-2,2-dimethyltetrahydrofuran[2,3-d][1,3]dioxolan-5-yl)methanone 
• 1018898-84-4 acetic acid (3S,4R,5S,6S)-2,4,5-triacetoxy-6-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-tetrahydropyran-3-yl ester 

Relevant articles and documents

Process development of sotagliflozin, a dual inhibitor of sodium- Glucose cotransporter-1/2 for the treatment of diabetes

The development of an efficient manufacturing process for sotagliflozin (LX4211), a dual inhibitor of sodium- glucose cotransporter-1/2 (SGLT-1/2) for the treatment of diabetes, is described. Sotagliflozin features five contiguous chiral centers on the carbohydrate core flanked by a thioether group and a biaryl moiety. Three chiral centers are obtained from the starting material L-xylose, while the other two were established (or modified) via three highly stereoselective transformations: Luche reduction (dr: 97/3), dynamic kinetic resolution of anomeric hemiacetal (dr: 95/5), and Lewis acid-promoted thiolation (dr: 1000/ 1). Global deprotection of the resulting penultimate intermediate with catalytic sodium methoxide followed by recrystallization furnishes sotagliflozin. The longest linear sequence consists of 10 steps from L-xylose with an overall yield of 40%. This process has been performed on multi-hundred kilogram batches to satisfy the drug substance development demands.

COMPOSITIONS COMPRISING (2S,3R,4R,5S,6R)-2-(4- CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL

Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

Glucopyranosyl derivative and application thereof in medicine

The invention relates to a glucopyranosyl derivative as a sodium-dependent glucose transporter (SGLT) inhibitor, a pharmaceutical composition containing the derivative and an application thereof in medicine, and in particular to the glucopyranosyl derivative as shown in a formula (I) or a pharmaceutically acceptable salt or all stereisomers thereof, or use of the pharmaceutical composition containing the derivative and the derivative and the pharmaceutical composition for preparing medicines treating diabetes and diabetes related diseases.